Objective: The aim of this study was to assess a risk-adapted strategy for stage I seminoma guided by the presence of rete testis invasion. Methods: Between January 2013 and December 2015, a total of 135 consecutive patients with stage I seminoma from 18 Spanish tertiary hospitals were included in a prospective multicenter study. Median patient age was 38 years (range 22–60). Preoperative beta-human chorionic gonadotropin was elevated in 9.6% of patients. Rete testis invasion was present in 47.4% of patients. After orchiectomy, subjects with rete testis invasion were treated with 2 courses of adjuvant carboplatin (area under the curve of 7, with 21-day interval). Those without this risk factor were managed by surveillance. Disease-free survival (DFS) and overall survival (OS) were estimated with the Kaplan-Meier method. Results: After a median follow-up time of 33 months, only 6 relapses were recorded (5 on surveillance, 1 after carboplatin). These cases were rescued with BEP or EP chemotherapy, and all 135 patients are currently disease free without sequelae. Three-year DFS was 92.0 and 98.2% for patients on surveillance and after carboplatin, respectively. Three-year OS was 100%. Conclusion: A risk-adapted approach based on rete testis invasion as a single risk factor is feasible and yielded an excellent outcome with a 3-year DFS of 94.9%.

Keywords:
Adjuvant chemotherapy, Carboplatin, Rete testis invasion, Seminoma, Surveillance
1.
Kollmannsberger C, Tandstad T, Bedard PL, et al: Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015; 33: 51–57.
2.
Nichols CR, Roth B, Albers P, et al: Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 2013; 31: 3490–3493.
3.
Oldenburg J, Aparicio J, Beyer J, et al: Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 2015; 26: 833–838.
4.
Warde P, Specht L, Horwich A, et al: Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20: 4448–4452.
5.
Chung P, Daugaard G, Tyldesley S, et al: Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med 2015; 4: 155–160.
6.
Mortensen MS, Lauritsen J, Gundgaard MG, et al: A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 2014; 66: 1172–1178.
7.
Tandstad T, Ståhl O, Dahl O, et al: Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol 2016; 27: 1299–1304.
8.
Aparicio J, García del Muro X, Maroto P, et al: Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003; 14: 867–872.
9.
Aparicio J, Germà JR, García del Muro X, et al: Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005; 23: 8717–8723.
10.
Aparicio J, Maroto P, García del Muro X, et al: Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 2011; 29: 4677–4681.
11.
American Joint Committee on Cancer: Testis; in Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A (eds): AJCC Cancer Staging Handbook, ed 7. New York, Springer, 2010, pp 539–546.
12.
Aparicio J, Maroto P, García del Muro X, et al: Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 2014; 25: 2173–2178.
13.
Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A: Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance – a systematic review. Urol Oncol 2017, Epub ahead of print.
14.
Aparicio J, Maroto P, Sastre J, Germà JR; Spanish Germ Cell Cancer Group: Re: Mette Saksø Mortensen, Jakob Lauritsen, Maria Gry Gundgaard MG, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 2014; 66: 1172–8. Eur Urol 2015; 67:e93–e94.
15.
Fischer S, Tandstad T, Wheater M, et al: Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma. J Clin Oncol 2017; 35: 194–200.
16.
Ondrusova M, Balogova S, Lehotska V, Kajo K, Mrinakova B, Ondrus D: Controversies in the management of clinical stage I testicular seminoma. Cent European J Urol 2016; 69: 35–39.
17.
Dieckmann KP, Dralle-Filiz I, Matthies C, et al; German Testicular Cancer Study Group: Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol 2016; 142: 1599–1607.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.